ISOPLEXIS CORP (ISO) Stock Price, Forecast & Analysis
USA - NASDAQ:ISO - US4650051067 - Common Stock
ISO Key Statistics, Chart & Performance
The current stock price of ISO is 0.7616 USD. In the past month the price decreased by -29.48%. In the past year, price decreased by -79.08%.
ISO Latest News, Press Relases and Analysis
ISO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 25.84 | 218.53B | ||
| DHR | DANAHER CORP | 28.69 | 158.40B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 161.67 | 49.06B | ||
| A | AGILENT TECHNOLOGIES INC | 26.94 | 41.62B | ||
| IQV | IQVIA HOLDINGS INC | 18.97 | 37.50B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 33.53 | 28.90B | ||
| WAT | WATERS CORP | 29.87 | 22.58B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 36.97 | 18.79B | ||
| ILMN | ILLUMINA INC | 27.68 | 18.55B | ||
| MEDP | MEDPACE HOLDINGS INC | 41.27 | 16.58B | ||
| TEM | TEMPUS AI INC | N/A | 11.90B | ||
| RVTY | REVVITY INC | 19.36 | 10.76B |
Related stock screener links
About ISO
Company Profile
IsoPlexis Corp. engages in the development of curative medicines and personalized therapeutics. The company is headquartered in Branford, Connecticut and currently employs 290 full-time employees. The company went IPO on 2021-10-08. The firm is engaged in building solutions to develop curative medicines and personalized therapeutics. The firm's single-cell proteomics systems reveal biological activity in small subsets of cells, allowing researchers to connect directly to in-vivo biology and develop precise and personalized therapies. Its focuses on developing applications of its platform for cancer immunology and cell and gene therapy. The firm's platform is comprised of IsoLight and IsoSpark instruments, IsoCode and CodePlex chip consumables, and IsoSpeak software. Its IsoLight and IsoSpark instruments are designed to be automated benchtop proteomic hubs. Its IsoCode chips use its technology proteomic barcoding to capture single-cell protein information. Its CodePlex chips technology is used to test multiplexed bulk proteins. The Company’s IsoSpeak software provides automated data analysis and accelerated insights with a push-button user interface.
Company Info
ISOPLEXIS CORP
35 Ne Industrial Road
Branford CONNECTICUT US
CEO: Sean Mackay
Employees: 290
Phone: 12032084111.0
ISOPLEXIS CORP / ISO FAQ
What does ISO do?
IsoPlexis Corp. engages in the development of curative medicines and personalized therapeutics. The company is headquartered in Branford, Connecticut and currently employs 290 full-time employees. The company went IPO on 2021-10-08. The firm is engaged in building solutions to develop curative medicines and personalized therapeutics. The firm's single-cell proteomics systems reveal biological activity in small subsets of cells, allowing researchers to connect directly to in-vivo biology and develop precise and personalized therapies. Its focuses on developing applications of its platform for cancer immunology and cell and gene therapy. The firm's platform is comprised of IsoLight and IsoSpark instruments, IsoCode and CodePlex chip consumables, and IsoSpeak software. Its IsoLight and IsoSpark instruments are designed to be automated benchtop proteomic hubs. Its IsoCode chips use its technology proteomic barcoding to capture single-cell protein information. Its CodePlex chips technology is used to test multiplexed bulk proteins. The Company’s IsoSpeak software provides automated data analysis and accelerated insights with a push-button user interface.
Can you provide the latest stock price for ISOPLEXIS CORP?
The current stock price of ISO is 0.7616 USD. The price increased by 2.78% in the last trading session.
What is the dividend status of ISOPLEXIS CORP?
ISO does not pay a dividend.
What is the ChartMill rating of ISOPLEXIS CORP stock?
ISO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Would investing in ISOPLEXIS CORP be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ISO.
ISO Technical Analysis
ISO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ISO. Both the profitability and financial health of ISO have multiple concerns.
ISO Financial Highlights
Over the last trailing twelve months ISO reported a non-GAAP Earnings per Share(EPS) of -2.7. The EPS decreased by -14.08% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 1.12 |
ISO Forecast & Estimates
9 analysts have analysed ISO and the average price target is 1.63 USD. This implies a price increase of 114.29% is expected in the next year compared to the current price of 0.7616.
For the next year, analysts expect an EPS growth of 48% and a revenue growth 49.37% for ISO